SE9604296D0 - New pharmaceutical formulation of polypeptides - Google Patents
New pharmaceutical formulation of polypeptidesInfo
- Publication number
- SE9604296D0 SE9604296D0 SE9604296A SE9604296A SE9604296D0 SE 9604296 D0 SE9604296 D0 SE 9604296D0 SE 9604296 A SE9604296 A SE 9604296A SE 9604296 A SE9604296 A SE 9604296A SE 9604296 D0 SE9604296 D0 SE 9604296D0
- Authority
- SE
- Sweden
- Prior art keywords
- lipid
- pharmaceutical formulation
- new pharmaceutical
- polypeptides
- relates
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 5
- 238000009472 formulation Methods 0.000 abstract 4
- 150000002632 lipids Chemical class 0.000 abstract 4
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 241000590002 Helicobacter pylori Species 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 229940037467 helicobacter pylori Drugs 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9604296A SE9604296D0 (sv) | 1996-11-22 | 1996-11-22 | New pharmaceutical formulation of polypeptides |
| PCT/SE1997/001927 WO1998022135A1 (en) | 1996-11-22 | 1997-11-18 | Pharmaceutical lipid aggregate with helicobacter pylori antigen and negatively charged lipid |
| AU51418/98A AU5141898A (en) | 1996-11-22 | 1997-11-18 | Pharmaceutical lipid aggregate with helicobacter pylori antigen and negatively charged lipid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9604296A SE9604296D0 (sv) | 1996-11-22 | 1996-11-22 | New pharmaceutical formulation of polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SE9604296D0 true SE9604296D0 (sv) | 1996-11-22 |
Family
ID=20404716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE9604296A SE9604296D0 (sv) | 1996-11-22 | 1996-11-22 | New pharmaceutical formulation of polypeptides |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU5141898A (sv) |
| SE (1) | SE9604296D0 (sv) |
| WO (1) | WO1998022135A1 (sv) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| EP2204186B1 (en) * | 1999-02-17 | 2016-04-06 | CSL Limited | Immunogenic complexes and methods relating thereto |
| GB0008879D0 (en) * | 2000-04-12 | 2000-05-31 | Astrazeneca Ab | Polypeptide delivery system |
| GB0008877D0 (en) * | 2000-04-12 | 2000-05-31 | Astrazeneca Ab | Polypeptide delivery system |
| GB0010371D0 (en) * | 2000-04-29 | 2000-06-14 | Astrazeneca Ab | Helicobacter pylori antigens |
| US11197916B2 (en) | 2007-12-28 | 2021-12-14 | Takeda Pharmaceutical Company Limited | Lyophilized recombinant VWF formulations |
| TWI600437B (zh) | 2007-12-28 | 2017-10-01 | 巴克斯歐塔公司 | 重組ｖｗｆ調配物 |
| CN102176907A (zh) * | 2008-10-08 | 2011-09-07 | 免疫解决方案有限公司 | 用于产生粘膜免疫的口服疫苗 |
| HRP20130414T1 (en) | 2008-10-21 | 2013-06-30 | Baxter International Inc. | Lyophilized recombinant vwf formulations |
| CA3007036A1 (en) * | 2015-12-14 | 2017-06-22 | Technische Universitat Munchen | Helicobacter pylori vaccines |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5643574A (en) * | 1993-10-04 | 1997-07-01 | Albany Medical College | Protein- or peptide-cochleate vaccines and methods of immunizing using the same |
-
1996
- 1996-11-22 SE SE9604296A patent/SE9604296D0/sv unknown
-
1997
- 1997-11-18 WO PCT/SE1997/001927 patent/WO1998022135A1/en not_active Ceased
- 1997-11-18 AU AU51418/98A patent/AU5141898A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU5141898A (en) | 1998-06-10 |
| WO1998022135A1 (en) | 1998-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY119003A (en) | Bacterial antigens and vaccine compositions | |
| ES2112838T3 (es) | Peptidos receptores de celulas t como agentes terapeuticos para enfermedades autoinmunitarias y malignas. | |
| TR200100936T2 (tr) | Terapötik aşılama | |
| IS4518A (is) | Nýtt lyfjaform fyrir bóluefni | |
| AR006999A1 (es) | Una composición inmunogénica, terapéutica o profiláctica , que comprende un polipéptido omp106 aislado, un anticuerpo aislado que se liga a dicho polipéptido y una vacuna que lo comprende. | |
| PT851927E (pt) | Compostos para imunoterapia e diagnostico de tuberculose | |
| ATE229978T1 (de) | Helicobacter proteine und impstoffe | |
| KR890701758A (ko) | 재조합 dna에서 유도한 보르데텔라 외독소 소단위체의 유사체 및 그를 포함하는 백신 | |
| WO1998053075A3 (en) | Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use | |
| SE9604296D0 (sv) | New pharmaceutical formulation of polypeptides | |
| KR910018033A (ko) | 악티노바실루스 플루로뉴모니아(Actinobacillus pleuropneumoniae) 서브유니트 백신 | |
| Rask et al. | Mucosal and systemic antibody responses after peroral or intranasal immunization: Effects of conjugation to enterotoxin B subunits and/or of co‐administration with free toxin as adjuvant | |
| CA2014033A1 (en) | Compositions and treatments for pneumonia in animals | |
| BR9810907A (pt) | Anticorpos monoclonais e policlonais, peptìdeo suscetìvel de gerar um anticorpo, agente imunogênico, sequência de nucleotìdeos, composição farmacêutica, uso de pelo menos um anticorpo, kit de diagnóstico, e, processo para preparar um agente imunogênico | |
| AU1813701A (en) | Interleukin-1 muteins useful as vaccine adjuvants | |
| BR9812240A (pt) | Proteìna g alterada ou polipeptìdeo do rsv, uso da mesma, molécula de ácido nucleico codificando uma proteìna g alterada ou um polipeptìdeo do rsv, construção do ácido nucleico, célula hospedeira recombinante, processos de produção de uma proteìna g alterada ou polipeptìdeo do rsv composição imunogênica, de indução de uma resposta imune em um vertebrado, de inibir a indução do aumento da doença após a vacinação e subsequente infecção de um vertebrado com o rsv e de imunização de um vertebrado contra o rsv, composição de vacina, vacina, e, composição imunogênica | |
| FI955150A0 (sv) | Immunogena formulationer av OspC-antigevacciner för förebyggande och behandling av lymsjukdom och rekombinantmetoder för framställning av antigenerna | |
| Ogawa et al. | Humoral and cellular immune responses to the fimbriae of Porphyromonas gingivalis and their synthetic peptides | |
| DE69415462D1 (de) | Synthetischen peptiden und impfstoffe gegen parvovirus | |
| WO1993014206A3 (en) | Synthetic peptides for a rubella vaccine | |
| WO1999051188A3 (en) | A polypeptide comprising the amino acid of an n-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof | |
| US8647636B2 (en) | Low antigen-dose immunization utilizing overlapping peptides for maximizing T-helper cell 1 (Th1) immunity against a pathogen | |
| PE20010237A1 (es) | GEN DERIVADO DE LAWSONIA Y POLIPEPTIDOS OmpH, PEPTIDOS Y PROTEINAS RELACIONADOS Y SUS USOS | |
| SE9604322D0 (sv) | Bacterial antigens and vaccine compositions II | |
| ATE385809T1 (de) | Saponin-zusammensetzungen und deren verwendung |